Best Practice & Research Clinical Haematology Volume 24, Issue 1 March 2011

15216926_00240001_cov150h......Page 1
1......Page 2
Introduction......Page 3
Introduction......Page 5
Embryonic tissue derived stem cell......Page 6
Stem cells derived from non-embryonic tissues with broader potential......Page 7
Isolation and characteristics of rodent MAPC......Page 8
Hepatic differentiation......Page 9
What is the developmental analog of rodent MAPC?......Page 10
References......Page 11
A brief historical and nomenclatural background......Page 14
Evidence of threshold doses for effective transplantation......Page 82
Can we call MSCs “Stem Cells”?......Page 15
Expansion/Differentiation and heterogeneity......Page 16
MPC: how to find the needle in a haystack?......Page 17
What other markers could be used?......Page 18
All the same or different members of the same family with the same outfit?......Page 19
In disguise, can we hunt them down?......Page 21
Rationale for ex vivo expansion......Page 22
Characteristics of bone marrow-derived MSC......Page 26
Prospective isolation of MSC......Page 27
Prospective isolation of MSC subsets......Page 29
Concluding remarks......Page 34
References......Page 35
A seminal experiment marking the birth of two key concepts......Page 38
The multiple meanings of a niche......Page 39
Heterotopic transfer of the HME......Page 40
Mesenchymal stem cells for treatment of tissue toxicity and hemorrhages......Page 67
Three players for a dual niche......Page 42
Osteoblasts vs. osteogenic lineage cells......Page 43
Stromal cells are osteoprogenitors, and are vascular cells......Page 44
The microvascular connection......Page 45
Conflict of interest......Page 46
References......Page 47
Mesenchymal stem cells and autoimmune diseases......Page 49
MSC for the treatment of autoimmune diseases......Page 50
Inflammatory environment and plasticity of MSC immunomodulatory activity......Page 52
References......Page 55
Neuroprotective features of mesenchymal stem cells......Page 58
Neuroprotective properties of MSC......Page 59
Funding......Page 61
References......Page 62
Graft-versus-host disease and toxicity in hematopoietic stem cell transplantation......Page 64
Mesenchymal stem cells for treatment of severe acute graft-versus-host disease......Page 65
Conclusion......Page 68
References......Page 69
Ex vivo expansion of mesenchymal stromal cells......Page 72
Ex vivo isolation and characterization of MSCs......Page 73
Ex vivo expansion of MSCs......Page 75
Other safety issues related to ex vivo expanded MSCs......Page 76
Conclusions......Page 77
References......Page 78
Mesenchymal stem cells in ex vivo cord blood expansion......Page 81
Concerns associated with ex vivo expansion......Page 83
Ex vivo CB MNC/MSC co-culture......Page 84
Rationale for the use of “Off-The-Shelf” MSC for the clinical protocol......Page 85
Summary......Page 86
References......Page 87
12......Page 91